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The currently available anticonvulsant drugs
are effective in reducing the severity and number of
seizures in less than 80% of the treated patients (1).
Moreover, their usage is associated with side-effects
ranging from cosmetic (gingival hyperplasia) to life-
-threatening (hepatotoxicity, megaloblastic anemia)
(2, 3). Thus, the evolution of novel antiepileptic
agents is of urgent necessity. It is well known that
numerous derivatives with anticonvulsant activity
do contain 5- or 6-membered heterocyclic rings, one
or two carbonyl groups, as well as an aromatic sys-
tem (4, 5). Among compounds investigated for their
anticonvulsant activity, one of the structural features
that play a significant role for their enhanced activi-
ty is just an amide fragment (6-8). 
The study carried out by Scott at al. (9, 10) on
a group of spiro[4.5] or spiro[4.4] carboxylic acids
as cyclic analogues of valproic acid has demonstra-
ted an anticonvulsant activity of these compounds.
Further investigation of the group of spirosuccinimi-
des (11) has revealed a key role of the cyclic system
connected with an imide fragment through a spiro
carbon atom, regarding the influence of compounds
of that type on the anticonvulsant activity. 
Following these findings, in the course of de-
veloping some new, potentially anticonvulsant com-
pounds, our attention has been focused on a group of
3-substituted pyrrolidine-2,5-diones with various
substituents at the nitrogen atom (12-15). Recently,
we have shown that a great number of pyrrolidine-
-2,5-dione derivatives with a 4-arylpiperazine moie-
ty at the N1 position, have exhibited a notable anti-
convulsant activity (16), especially in the maximum
electroshock (MES) test (e.g. N-{[4-(3-chloro-
phenyl)-piperazin-1-yl]-methyl}-3-(2-chloro-phe-
nyl)-pyrrolidine-2,5-dione; ED50 = 14.20 mg/kg).
On the contrary, 3-spirocycloalkyl analogues were
effective in the sc. Met test (17). 
In our previous study, we described the synthe-
sis and physicochemical properties of N-phenyl and
N-benzyl amides of 3-spirocycloalkylpyrrolidine-
-2,5-dione acetic and benzoic acids which, unfortu-
nately, were devoid of any anticonvulsant activity
(18). It is well known that the 4-arylpiperazine moie-
ty plays an essential role as a pharmacophoric substi-
tuent, and is present in many compounds exhibiting
a variety of pharmacological effects (19-20). These
findings and the information given above have
prompted us to carry out the synthesis of new amides
of (2-aza-1,3-dioxospiro[4.5]dec-2-yl)-acetic acid in
which we have replaced the phenyl- and benzyl-ami-
nes with a 4-arylpiperazine fragment having various
substituents at the aryl ring (see Figure 1).
All the newly obtained compounds IIñX were
tested for their anticonvulsant activity through the
Anticonvulsant Screening Program (ASP) of the Na-
tional Institute of Neurological Disorders and Stro-
ke (NINDS) in the maximal electroshock (MES),
subcutaneous metrazole (sc. Met) and neurotoxicity
(Tox) tests. The starting 1-carboxy-1-cyclohexane-
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-acetic acid was synthesized by a method previously
reported (21). The synthesis and physicochemical
data of (2-aza-1,3-dioxo-spiro[4.5]dec-2-yl)-acetic
acid [I] were described in our recent publication
(18). The reaction of acid [I] with the appropriately
substituted 4-arylpiperazines, in the presence of car-
bonyldiimidazole (CDIM) (22) in DMF, finally led
to N-4-arylpiperazin-1-yl amides of (2-aza-1,3-dio-
xospiro[4.5]dec-2-yl)-acetic acid [II-X]. 
1H-NMR spectra of the synthesized compounds [II-
-X] were studied. They 1H NMR spectra revealed
a few characteristic chemical shifts of the investi-
gated amides. The chemical shifts of the cyclo-
Figure 1. Structural elements and the difference between inactive and active anticonvulsant compounds
Table 1. Physicochemical data for compounds II-X
Molecular Analyses




II C21H27O3N3 69 68.27/68.5 7.37/7.5 11.37/11.4 0.54A
369.5 176-178 0.80 B
III C21H26O3N3F1 65 65.10/65.0 6.76/6.9 10.85/10.8 0.64 A
387.5 136-138 0.85 B
IV C21H26O3N3Cl1 62 62.45/62.2 6.49/6.7 10.40/10.4 0.62 A
403.9 162-164 0.82 B
V C21H26O3N3Cl1 81 62.45/6.3 6.49/6.8 10.40/10.1 0.58 A
403.9 145-147 0.85 B
VI C22H29O3N3 75 68.90/69.0 7.62/7.7 10.96/10.9 0.56 A
383.49 150-152 0.84 B
VII C22H29O3N3 71 68.90/6.6 7.62/7.9 10.96/10.7 0.62 A
383.5 167-169 0.86 B
VIII C22H29O4N3 64 66.15/65.9 7.32/7.4 10.52/10.5 0.44A
399.5 162-164 0.80B
IX C22H29O4N3 68 66.15/65.9 7.32/7.4 10.52/10.4 0.52A
399.5 134-136 0.81B
X C22H26O3N3F3 63 60.47/60.2 6.00/6.1 9.62/9.5 0.58 A
437.5 179-181 0.78 B
a Solvents: A ñ benzene : ethyl acetate: acetone (10 : 5 : 1), B ñ butanol : acetic acid : water (5 : 4 : 1)
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Table 2. 1H NMR spectral data for compounds II-X
No. 1H-NMR δ (ppm)/CDCl3
II 1.24-1.93 (10H, m, cyclohexane), 2.69 (2H, s, imide), 3.19-3.30 (4H, dt, piperazine, J = 5.08 Hz),
3.66-3.81 (4H, dt, piperazine, J = 5.08 Hz), 4.36 (2H, s, -CH2-), 6.94-7.36 (5H, m, arom.)
III 1.23-1.95 (10H, m, cyclohexane), 2.69 (2H, s, imide), 3.09-3.19 (4H, dt, piperazine, J= 5.02 Hz),
3.67-3.82 (4H, dt, piperazine, J = 4.90 Hz), 4.36 (2H, s, -CH2-), 6.95-7.15 (4H, m, arom.)
IV 1.37-1.95 (10H, m, cyclohexane), 2.69 (2H, s, imide), 3.05-3.16 (4H, dt, piperazine, J = 4.95 Hz),
3.67-3.83 (4H, dt, piperazine, J = 4.95 Hz), 4.36 (2H, s, -CH2-), 7.03-7.44 (4H, m, arom.)
V 1.40-1.95 (10H, m, cyclohexane), 2.69 (2H, s, imide), 3.20-3.31 (4H, dt, piperazine, J = 5.08 Hz),
3.65-3.80 (4H, dt, piperazine, J = 5.02 Hz), 4.35 (2H, s, -CH2-), 6.81-7.29 (4H, m, arom.)
VI 1.36-1.96 (10H, m, cyclohexane), 2.36 (3H, s, -CH3) 2.69 (2H, s, imide), 3.18-3.28 (4H, dt,
piperazine, J = 5.09 Hz), 3.65-3.80 (4H, dt, piperazine, J = 4.90 Hz), 4.36 (2H, s, -CH2-), 6.76-7.28
(4H, m, arom.)
VII 1.24-1.93 (10H, m, cyclohexane), 2.36 (3H, s, -CH3), 2.69 (2H, s, imide), 3.18-3.29 (4H, dt,
piperazine, J = 4.95 Hz), 3.65-3.80 (4H, dt, piperazine, J = 4.95 Hz), 4.36 (2H, s, -CH2-), 6.78-7.29
(4H, m, arom.)
VIII 1.23-1.94 (10H, m, cyclohexane), 2.69 (2H, s, imide), 3.06-3.17 (4H, dt, piperazine, J = 4.68 Hz),
3.67-3.83 (4H, dt, piperazine, J = 4.68 Hz), 3.92 (3H, s, -OCH3) 4.36 (2H, s, -CH2-), 6.91-7.11 (4H,
m, arom.)
IX 1.23-1.94 (10H, m, cyclohexane), 2.69 (2H, s, imide), 3.19-3.30 (4H, dt, piperazine, J = 5.09 Hz),
3.65-3.80 (4H, dt, piperazine, J = 5.09 Hz), 3.83 (3H, s, -OCH3) 4.35 (2H, s, -CH2-), 6.50-7.30 (4H,
m, arom.)
X 1.23-1.94 (10H, m, cyclohexane), 2.69 (2H, s, imide), 3.21-3.32 (4H, dt, piperazine, J = 5.30 Hz),
3.64-3.79 (4H, dt, piperazine, J = 4.68 Hz), 4.32 (2H, s, -CH2-), 7.07-7.41 (4H, m, arom.)
No II III IV V VI VII VIII IX X
R H 2-F 2-Cl 3-Cl 2-CH3 3-CH3 2-OCH3 3-OCH3 3-CF3
Scheme 1.
i DMF, ii room temp., 24 h, cold water.
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hexane ring were shown as multiplets within the
range of δ 1.24-1.96 ppm. Two protons of pyrro-
lidine-2,5-dione in all the compounds studied were
shown as singlets at δ 2.69 ppm. Protons of the pi-
perazine ring were observed as two dublets of tri-
plets within the range of δ 3.09-3.32 ppm and δ
3.64-3.84 ppm (J = 5.0 Hz). The resonance signal
of the methylene spacer between the imide nitro-
gen and the amide bond occurred as a singlet at δ
4.36 ppm. The signals of aromatic protons appeared
as multiplets within the range of δ 6.50-7.41 ppm.
The protons of the methyl group [VI, VII] were
observed as a singlet at δ 2.36 ppm, while three
protons of the methoxy group [VIII, IX] also 
occurred as a singlet at δ 3.92 ppm.
EXPERIMENTAL
Chemistry
Melting points (OC) are uncorrected. 1H-NMR
spectra were obtained with a Varian Mercury spec-
trometer working at 300 MHz. Chemical shifts we-
re described as parts per million (δ ppm), (CH3)4Si
(TMS) was used as an internal standard. Signal mul-
tiplicities were given by the following abbrevia-
tions: s (singlet), dt (doublet of triplets), m (multi-
plet). The purity of the compounds was checked by
thin-layer chromatography (TLC) performed on
Merck silica gel GF254 aluminium sheets using the
following developing systems: A ñ benzene : ethyl
acetate: acetone (10 : 5 : 1), B ñ butanol : acetic acid
: water (5 : 4 : 1). The spots were detected by means
of their absorption under UV light and by visualiza-
tion with 0.05 mol I2 in 10% HCl.
GENERAL PROCEDURE FOR PREPARING N-4-
ARYLPIPERAZIN-1-YL AMIDES OF (2-AZA-1,3-
DIOXOSPIRO[4.5]DEC-2-YL) ACETIC ACID 
[II-X]
(2-Aza-1,3-dioxospiro[4.5]dec-2-yl)-acetic
acid [I] (0.02 mol) was dissolved in 20 ml of DMF,
and then N,N-carbonyldiimidazole (0.02 mol) was
added. The mixture was stirred for 0.5 h at room
temperature. Afterwards, the appropriate substituted
4-arylpiperazine (0.02 mol) was added. After 24 h of
stirring at room temperature, the final reaction mi-
xture was left in an ice-cold bath, and next, the pro-
duct was precipitated with cold water; it was puri-
fied by recrystallization from isopropyl alcohol.
Physicochemical data, yields, elemental analyses
and Rf values are presented in Table 1. The 1H-NMR
spectral data are shown in Table 2.
PHARMACOLOGY
Preliminary pharmacological tests of com-
pounds II-X were provided through the Antiepilep-
tic Drug Development (ADD) Program (Epilepsy
Branch, Neurological Disorders Program, National
Institute of the Neurological and Communicative
Disorders and Stroke (NINCDS), Bethesda) by test-
ing procedures which had been described earlier
(23, 24). Phase I studies of the investigated compo-
unds involved three tests: a maximum electroshock
(MES), a subcutaneous metrazole (sc. Met) and a ro-
tarod test for neurological toxicity (TOX).
In the MES and sc. Met tests, mice are tested
for 30 min and 4 h, using the following doses 30,
100 and 300 mg/kg of tested compound. The com-
pound was injected intraperitoneally as a suspension
in a 0.5% methylcellulose/water mixture, in a volu-
me of 0.01ml/g body weight. In the MES seizure test
an electrical stimulus of duration 0.2 s (50mA) is de-
livered via corneal electrodes.
In the sc. Met test, a dose of 85 mg/kg metra-
zole (in mice) was administrated subcutaneously.
This produced clonic seizures lasting for a period of
at least five seconds in 97 per cent (CD97) of animals
tested. Absence of clonic seizure in the observed ti-
me of period indicated the ability of compound to
abolish the effect of metrazole on seizure threshold.
A neurological toxicity test (TOX) induced by
a compound was detected in mice using a standardi-
zed rotarod test. Untreated control of mice, when
placed on a 6 r.p.m rotation rod, can maintain their
equilibrium for a prolonged period of time. Neuro-
logical impairment can be demonstrated by the ina-
bility of a mouse to maintain equilibrium for one
min. in each of three successive trials. For these
experiments, four animals were used at 30 and 300
mg/kg and eight at 100 mg/kg. 
The compounds were classified according to
the following categories: anticonvulsant activity at
100 mg/kg or less (class 1), anticonvulsant activity
at doses higher than 100 mg/kg (class 2), compo-
unds inactive at 300 mg/kg (class 3). 
RESULTS
The initial anticonvulsant activity and neuroto-
xicity data on the compounds in question are presen-
ted in Table 3. The MES and sc. Met tests have be-
come the most widely employed seizure models for
an early identification and throughout screening of
investigational antiepileptic drugs (25). The tested
compounds [III-VI and VIII-IX] at the three doses
used (30, 100 and 300 mg/kg) were found to be de-
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voided of activity in both the MES and the sc. Met
tests and showed no neurotoxicity at any of the ad-
ministrated doses. Compounds II, VII and X reve-
aled anti-sc. Met activity indicating their ability to
elevate the seizure threshold. In that test, the most
potent was 3-methylphenylpiperazin-1-yl amide of
(2-aza-1,3-dioxo-spiro[4.5]dec-1-yl)-acetic acid
[VII] and protected animals at doses of 30, 100 and
300 mg/kg after 0.5 h. Compound II without substi-
tuents at the aryl ring and its 3-CF3 analogue X we-
re also active at doses of 100 and 300 mg/kg in the
same test.
In conclusion, as shown in Figure 1, the intro-
duction of a piperazine moiety as an amide fragment
in place of phenylamine plays an essential role in in-
ducing anticonvulsant activity. It is noteworthy that
also type and position of substituents at the aryl ring
are very important for this effect. As has been repor-
ted by many studies (26-31), the substitution of the
aryl ring with an electron-withdrawing -CF3 or an
electron-donating ñCH3 group was generally benefi-
cial to the biological activity. In the present study we
also obtained anticonvulsant active compounds with
-CH3 [VII] and -CF3 [X] substituents connected to
the aryl ring at position 3. In contrast, introduction
of substituents such as chlorines [III-V] or methoxy
group [VIII, IX] led to the loss of anticonvulsant ac-
tivity in both the tests used. 
In the nearest future, on the basis of the hither-
to obtained results we intend to synthesize some
Table 3. Anticonvulsant screening project (ASP) phase I in mice.
Comp. Dose MESa sc.Metb Toxc ASPd
mg/kg 0,5h 4h 0,5h 4h 0,5h 4h Class.
30 0/1 0/1 0/1 0/1 0/4 0/2
II 100 0/1 0/1 2/5 0/1 0/8 0/4 1
300 0/1 0/1 1/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
III 100 0/1 0/1 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IV 100 0/1 0/1 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
V 100 0/1 0/1 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VI 100 0/1 0/1 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 1/5 0/1 0/4 0/2
VII 100 0/1 0/1 1/1 0/1 0/8 0/4 1
300 0/1 0/1 1/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VIII 100 0/1 0/1 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IX 100 0/1 0/1 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
X 100 0/1 0/1 1/1 0/1 0/8 0/4 1
300 0/1 0/1 1/1 0/1 0/4 0/2
a) Maximal electroshock (number of animals protected/number of animals tested); b) Subcutaneous metrazole test (number
of animals protected/number of animals tested); c) Rotarod toxicity (number of animals exhibiting toxicity/number of ani-
mals tested); d) The ASP classification is as follows: 1 ñ anticonvulsant activity at doses of 100 mg/kg or lower; 2 ñ anti-
convulsant activity at doses higher than 100 mg/kg; 3 ñ compound inactive at a dose of 300 mg/kg.
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new 4-arylpiperazin-1-yl amides of (2-aza-1,3-dio-
xospiro[4.5]dec-1-yl)-propionic and butyric acid to
study the influence of the distance between the imi-
de nitrogen atom and piperazine moiety on the anti-
convulsant activity.
Subsequent studies will be published shortly.
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